Similarly, Schinke et al. [9] found that CXCL8-CXCR2 was overexpressed in the bone marrow cells of AML and MDS patients, with CXCR2 expression correlating with poor prognosis; after targeting and inhibiting the expression of CXCR2 via gene-editing technology and pharmacological means, the characteristics of stem cells in AML/MDS could be reduced, and the survival ability of cell lines could also be weakened, potentially serving as a therapeutic target for AML and MDS patients. Here, CXCL8 is linked to acute myeloid leukemia.